---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063990"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:57:29.796880+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharma Q1 net loss $17M; pipeline on track for data in H2 2025

## Summary
- Net loss of $17.0M ($1.39/share) vs $6.9M ($0.83) in Q1 2024; operating expenses rose to $19.8M.
- Cash and investments $132.8M; expected to fund operations through Q2 2027.
- CRB-701 Nectin-4 ADC dose optimization ongoing; RP2D expected Q4 2025; FDA Fast Track for cervical cancer.
- CRB-913 CB1 inverse agonist Phase 1 SAD/MAD started March 2025; completion Q3 2025; Phase 1b starts Q4 2025.
- CRB-601 anti-αvβ8 mAb Phase 1 dose escalation ongoing; completion expected Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-063990
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017025063990/0000950170-25-063990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017025063990/crbp-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063990
- JSON: https://secwatch.observer/filing/0000950170-25-063990.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063990.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.